Anabolic steroidAndrogenAnabolic steroidDHT-derivedNon-aromatisingInjectable

Drostanolone Enanthate

Also known as Masteron Enanthate · Drostanolone Enanthate · Mast E

Written by enwyReviewed 15 Jul 20262 sources0 comments

The long-ester version of drostanolone (Masteron), pharmacologically identical to the propionate but with a slower release allowing less frequent injection. It shares the same DHT-derived, non-aromatising, dry-hardening profile and the same androgenic side-effect pattern; only the ester and dosing frequency differ. Human clinical data are limited to the older propionate breast-cancer use.

01 Overview

Drostanolone enanthate delivers the identical active steroid as drostanolone propionate, attached to a longer enanthate ester that extends the half-life and lets users inject roughly twice weekly instead of every other day. The active-compound pharmacology — 2-alpha-methyl-DHT, non-aromatising, mildly anti-oestrogenic, cosmetically 'hardening' — is unchanged.

There is no separate clinical literature for the enanthate ester; its evidence base is that of drostanolone generally, so the research score reflects thin, largely dated and anecdotal human data. Because the ester is longer, steady-state takes longer to reach and the compound clears more slowly, mildly lengthening the detection window relative to the propionate.

02 Mechanism

Identical to drostanolone propionate — a DHT-derived androgen-receptor agonist that cannot aromatise — differing only in the enanthate ester's slower release and longer half-life.

03 Dosing

Tier	Dose	Route	Notes
Common	300–500 mg/wk	IM	Injected roughly twice weekly.
Heavy	500–600 mg/wk	IM	Best results at low body fat.

Ester comparison

Ester	Half-life	Injection freq.	Testosterone by mass

04 Effects

Effect	Magnitude	Evidence
Hardening / dry, defined lookSame cosmetic hardening as propionate; anecdotal, most visible when lean.		Anecdotal
Mild anti-oestrogenic effectInherited from drostanolone's documented anti-oestrogenic action.		Clinical
Less frequent injectionLonger ester reduces injection frequency versus propionate.		Observational

05 Side effects

Effect	Severity	Frequency	Evidence
Accelerated male-pattern hair lossPotent DHT derivative hastens scalp hair loss in the predisposed.	Moderate	Common	Observational
Acne and oily skinAndrogenic sebaceous stimulation.	Mild	Common	Observational
HPTA suppressionSuppresses endogenous testosterone.	Severe	Universal	Observational

06 Legal status

United States

Schedule III controlled substance

as of

United Kingdom

Class C controlled drug

as of

07 References

Drostanolone: pharmacology and historical oncology useBreast cancer / steroid literature

WADA Prohibited List - anabolic agentsWorld Anti-Doping Agency

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.